(FRE) Fresenius SE & Co. KGaA - Overview
Stock: Infusion, Nutrition, Disposables, Pumps, Devices
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 2.32% |
| Yield on Cost 5y | 3.08% |
| Yield CAGR 5y | 3.25% |
| Payout Consistency | 84.7% |
| Payout Ratio | 30.2% |
| Risk 5d forecast | |
|---|---|
| Volatility | 27.2% |
| Relative Tail Risk | -6.20% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.06 |
| Alpha | 26.07 |
| Character TTM | |
|---|---|
| Beta | 0.046 |
| Beta Downside | 0.135 |
| Drawdowns 3y | |
|---|---|
| Max DD | 22.08% |
| CAGR/Max DD | 0.94 |
Description: FRE Fresenius SE & Co. KGaA December 17, 2025
Fresenius SE & Co. KGaA (XETRA:FRE) is a German-based integrated health-care group that serves chronically ill patients through two main divisions: Fresenius Kabi, which supplies critical-care and nutrition products (e.g., parenteral nutrition, infusion pumps, apheresis and cell-therapy devices), and Fresenius Helios, which operates a network of hospitals and nursing facilities. The firm, originally founded in 1912 and renamed in 2011, is headquartered in Bad Homburg vor der Höhe.
Key performance indicators that analysts watch include: (1) **Helios EBITDA margin**, historically around 8-9 % and sensitive to occupancy rates and payer mix; (2) **Kabi’s organic sales growth**, typically 3-5 % YoY, driven by aging populations and increasing demand for home-infusion therapies; and (3) **Free cash flow conversion**, which has averaged 70-80 % of operating cash flow, underpinning the company’s dividend policy. Macro-level drivers are demographic aging in Europe, rising chronic disease prevalence, and the shift toward outpatient and home-based care, which together expand both product and service addressable markets.
For a deeper, data-rich assessment of FRE’s valuation and risk profile, consider exploring the analytical dashboards on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income: 1.14b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA -2.90 > 1.0 |
| NWC/Revenue: 11.17% < 20% (prev 13.28%; Δ -2.11% < -1%) |
| CFO/TA 0.05 > 3% & CFO 2.19b > Net Income 1.14b |
| Net Debt (11.18b) to EBITDA (3.34b): 3.34 < 3 |
| Current Ratio: 1.26 > 1.5 & < 3 |
| Outstanding Shares: last quarter (563.2m) vs 12m ago 0.21% < -2% |
| Gross Margin: 24.99% > 18% (prev 0.24%; Δ 2475 % > 0.5%) |
| Asset Turnover: 52.69% > 50% (prev 52.42%; Δ 0.27% > 0%) |
| Interest Coverage Ratio: 6.42 > 6 (EBITDA TTM 3.34b / Interest Expense TTM 344.0m) |
Altman Z'' 3.65
| A: 0.06 (Total Current Assets 12.06b - Total Current Liabilities 9.56b) / Total Assets 42.46b |
| B: 0.44 (Retained Earnings 18.60b / Total Assets 42.46b) |
| C: 0.05 (EBIT TTM 2.21b / Avg Total Assets 42.41b) |
| D: 1.42 (Book Value of Equity 32.91b / Total Liabilities 23.19b) |
| Altman-Z'' Score: 3.65 = AA |
Beneish M -2.73
| DSRI: 1.46 (Receivables 5.60b/3.82b, Revenue 22.35b/22.21b) |
| GMI: 0.95 (GM 24.99% / 23.82%) |
| AQI: 0.97 (AQ_t 0.49 / AQ_t-1 0.51) |
| SGI: 1.01 (Revenue 22.35b / 22.21b) |
| TATA: -0.02 (NI 1.14b - CFO 2.19b) / TA 42.46b) |
| Beneish M-Score: -2.73 (Cap -4..+1) = A |
What is the price of FRE shares?
Over the past week, the price has changed by -2.40%, over one month by -3.61%, over three months by -6.25% and over the past year by +29.88%.
Is FRE a buy, sell or hold?
What are the forecasts/targets for the FRE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 55.5 | 17.5% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 53 | 12.3% |
FRE Fundamental Data Overview January 26, 2026
P/E Trailing = 23.5951
P/E Forward = 13.4409
P/S = 1.2138
P/B = 1.463
P/EG = 0.3906
Revenue TTM = 22.35b EUR
EBIT TTM = 2.21b EUR
EBITDA TTM = 3.34b EUR
Long Term Debt = 9.53b EUR (from longTermDebt, last quarter)
Short Term Debt = 2.74b EUR (from shortTermDebt, last quarter)
Debt = 13.54b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 11.18b EUR (from netDebt column, last quarter)
Enterprise Value = 38.42b EUR (27.24b + Debt 13.54b - CCE 2.36b)
Interest Coverage Ratio = 6.42 (Ebit TTM 2.21b / Interest Expense TTM 344.0m)
EV/FCF = 31.75x (Enterprise Value 38.42b / FCF TTM 1.21b)
FCF Yield = 3.15% (FCF TTM 1.21b / Enterprise Value 38.42b)
FCF Margin = 5.41% (FCF TTM 1.21b / Revenue TTM 22.35b)
Net Margin = 5.11% (Net Income TTM 1.14b / Revenue TTM 22.35b)
Gross Margin = 24.99% ((Revenue TTM 22.35b - Cost of Revenue TTM 16.76b) / Revenue TTM)
Gross Margin QoQ = 23.70% (prev 26.12%)
Tobins Q-Ratio = 0.90 (Enterprise Value 38.42b / Total Assets 42.46b)
Interest Expense / Debt = 0.60% (Interest Expense 81.0m / Debt 13.54b)
Taxrate = 24.22% (116.0m / 479.0m)
NOPAT = 1.67b (EBIT 2.21b * (1 - 24.22%))
Current Ratio = 1.26 (Total Current Assets 12.06b / Total Current Liabilities 9.56b)
Debt / Equity = 0.73 (Debt 13.54b / totalStockholderEquity, last quarter 18.62b)
Debt / EBITDA = 3.34 (Net Debt 11.18b / EBITDA 3.34b)
Debt / FCF = 9.24 (Net Debt 11.18b / FCF TTM 1.21b)
Total Stockholder Equity = 18.96b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.69% (Net Income 1.14b / Total Assets 42.46b)
RoE = 6.03% (Net Income TTM 1.14b / Total Stockholder Equity 18.96b)
RoCE = 7.76% (EBIT 2.21b / Capital Employed (Equity 18.96b + L.T.Debt 9.53b))
RoIC = 5.41% (NOPAT 1.67b / Invested Capital 30.95b)
WACC = 4.21% (E(27.24b)/V(40.78b) * Re(6.08%) + D(13.54b)/V(40.78b) * Rd(0.60%) * (1-Tc(0.24)))
Discount Rate = 6.08% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 0.0 | Cagr: 0.0%
[DCF Debug] Terminal Value 85.14% ; FCFF base≈1.70b ; Y1≈1.52b ; Y5≈1.29b
Fair Price DCF = 49.24 (EV 38.91b - Net Debt 11.18b = Equity 27.73b / Shares 563.2m; r=5.90% [WACC]; 5y FCF grow -13.08% → 2.90% )
EPS Correlation: -12.73 | EPS CAGR: -49.48% | SUE: -4.0 | # QB: 0
Revenue Correlation: -84.91 | Revenue CAGR: -14.72% | SUE: -0.10 | # QB: 0
EPS next Year (2026-12-31): EPS=3.71 | Chg30d=-0.002 | Revisions Net=-1 | Growth EPS=+10.2% | Growth Revenue=+5.3%